GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year ...
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year First half fiscal 2026 revenue surpasses $2 million, up 36% year-over ...
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...
Aprea’s patent strategy is designed to secure durable global protection around its proprietary molecules, formulations, and therapeutic applications, to de-risk clinical development and maximize ...
Total Bookings: $2.79 million in contract value signed in 2025, 4.1X more than prior fiscal year Larger Deal Sizes: Continued expansion in average contract value, driven by enterprise-scale AI models, ...
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth ...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) and Sapu Bioscience today announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β ...
LIBERTY® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US ...
Neural-Network Based Cell Analysis This clearance follows four years of regulatory engagement with the FDA to validate AI-native diagnostics in clinical environments. Athelas Home uses ...
Equels will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and ...
About PsiThera PsiThera is a biotechnology company harnessing biologically relevant protein states and computational intelligence to create oral drugs for immune and inflammatory diseases—therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results